Published Date: 10 Mar 2023
This decision will ensure that effective drugs are available in all communities, and state pharmacies must:
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
Cancer and HIV Vaccines Enter the Therapeutic Era
2.
Higher Binge Drinking Rates Linked to New Cannabis Laws.
3.
Drugmaker Pulls Trodelvy's Bladder Cancer Approval
4.
Firefighters who eat better can combat cancer.
5.
Prostate cancer therapies: AI-based image analysis detects early organ damage
1.
Understanding Lymphedema: Symptoms, Causes, and Treatment
2.
A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology
3.
A Comprehensive Guide to Using an ABG Calculator for Accurate Diagnosis
4.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
5.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
5.
Navigating the Complexities of Ph Negative ALL - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation